Institution
University of Florence
Education•Florence, Toscana, Italy•
About: University of Florence is a education organization based out in Florence, Toscana, Italy. It is known for research contribution in the topics: Population & Carbonic anhydrase. The organization has 27292 authors who have published 79599 publications receiving 2341684 citations. The organization is also known as: Università degli studi di Firenze & Universita degli studi di Firenze.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: A unifying framework is introduced to understand existing approaches to investigate the universal approximation problem using feedforward neural networks, and two training algorithms are introduced which can determine the weights of feedforward Neural Network, with sigmoidal activation neurons, to any degree of prescribed accuracy.
530 citations
••
TL;DR: The presence of a functional and classical lymphatic system in the central nervous system suggests that current dogmas regarding brain tolerance and the immune privilege of the brain should be revisited in autism, which intersect with observations of increased extra-axial CSF (EAF) in the autism population.
Abstract: Autism spectrum disorders (ASD) represent an apparent pandemic threat to child development with the current CDC data documenting ASD affecting over 2% of U.S. males of school age ([CDC] Developmental Disabilities Monitoring Network Surveillance Year 2010 Principal, 2014). ASD are likely a heterogeneous group of disorders with genetic and environmental causes resulting in similar phenotypes. Genetic contributions to autism are extremely heterogeneous and may involve synaptic formation and maturation. Thus, multiple genes involved in the formation, specification, and maintenance of synapses have been identified as risk factors for ASD development (Hahn et al., 2013). Also the rate of brain growth in the first 2 years of life may contribute to ASD. Although abnormally enlarged brain volumes and increased rates of brain growth during early childhood are observed only in a minority of ASD children, nevertheless there is evidence of abnormalities in posterior lobes and posterior brain networks during the first 2 years of life in ASD (Lainhart, 2015).
If the etiology of ASD is still mysterious, there is a growing consensus for the role of neuroinflammation in ASD pathogenesis (Fatemi et al., 2012), and the recent publication in Nature of the existence of the previously unknown meningeal lymphatic system, invites a closer evaluation of its potential significance to brain development (Louveau et al., 2015).
In 1983, Aarli speculated the fluid of the brain traveled along mysterious perivascular channels, and noted that immunological challenges could affect the integrity of the blood brain barrier (Aarli, 1983). It was then accepted that the exit pathway for immune cells trafficking through the CNS was via the arachnoid granulations. The new study in Nature provides us with a secondary pathway leading to deep cervical lymph nodes.
We concur with the comment (Louveau et al., 2015) that; “the presence of a functional and classical lymphatic system in the central nervous system suggests that current dogmas regarding brain tolerance and the immune privilege of the brain should be revisited.”
This feature is critically important with regard to the observations of immunological dysregulation in autism, which intersect with observations of increased extra-axial CSF (EAF) in the autism population. MRI scans were used (Shen et al., 2013) to evaluate the EAF of infants born into families with an existing autistic child. They were able to predict the future onset and severity of autism based on the findings of early and persistent increases in EAF. In a similar way, we were able to demonstrate increased EAF using transcranial ultrasonography and we too observed a correlation between increased severity of autistic symptoms and increased EAF scores (Bradstreet et al., 2014). The mechanisms responsible for such an increased EAF, however, remained unknown. The newly discovered meningeal lymphatic system might help explaining how immunological dysfunctions and peripheral chronic infection/inflammation may affect the meninges and, consequently, brain development.
Several evidences point to a connection between meninges and abnormal CNS development. Meningeal cells are involved in cortical development (Dragunow, 2013), and meningeal alterations in mice modeling ASD-like behaviors contribute to incorrect neurogenesis during development (Mercier et al., 2011). In 2012, Zarbalis et al. demonstrated that meningeal defects alter migration of cortical interneurons in a mouse model, thus further stressing the role of the meninges in the establishment of proper neuronal interconnections (Zarbalis et al., 2012).
The observations of increased EAF in the autism population with these new observations of a central lymphatic system connected to cervical lymph nodes, should direct more attention to the role of meningeal lymphatics in the pathogenesis of ASD. It further begs the question: “could inflammation-associated deficits in meningeal lymph drainage be the culprit for the observed increased EAF?”
Intersecting the increased EAF volume observations in ASD with the EAF drainage to deep cervical lymph nodes draws our attention to the pathogenetic potential of chronic infections leading to inflammation and subsequent deficit in lymphatic drainage.
Supporting the role of chronic infection/inflammation in ASD pathogenesis, multiple polyomaviral infections were observed to be significantly more common in the post-mortem brains of ASD individuals (Lintas et al., 2010) and ASD individuals show immune transcriptome alterations in the temporal cortex that seem to indicate immune dysregulation with consequent inflammation (Garbett et al., 2008). Piras et al. (2014) correlated anti-brain antibodies with specific deficits in ASD, thus reinforcing the notion that chronic inflammation is a common denominator that may lead to EAF increase because of impaired meningeal lymphatic drainage.
The existence of a classical lymphatic system in the CNS might also explain the nature of the lesions in the brains of autistic subjects, which we observed with ultrasonography and designated “cortical dysplasia” (Bradstreet et al., 2014). Inefficient drainage with focal accumulation of CSF in certain areas of the cortex might explain the hypoechogenic appearance of focal “patches,” which we consistently observed in autistic subjects. Accumulation of fluid that typically appears hypoechogenic in ultrasonography, might thus disrupt neuronal/glial networking by increasing the distance between cells and by increasing extracellular pressure on cells with consequent alteration of gene expression trough modification of the cytoskeleton (Knoll, 2010). Since Stoner et al. (2014) also observed “patches” of decreased transcription in autism related brain bank specimens, it is tempting to speculate that such alterations of gene expression may be associated with the accumulation of EAF and its effects on neuronal and glial function.
Finally, transcranial ultrasonography deserves more attention as a harmless and low-cost means of evaluating CSF fluid volumes and stratifying ASD children potentially at-risk for chronic CNS inflammatory disorders. Transcranial ultrasonography enables reproducible evaluation of EAF by measuring the distances between the arachnoid membrane and the cortical pia layer (subarachnoid space), and may thus help establishing the degree of meningeal lymphatic drainage deficit. Since the measures can be easily repeated, the technique could be used for monitoring the progression of the disease or for objectively assessing the efficacy of treatments.
In conclusion, the observation by Louveau et al. (2015) leads us to hypothesize that meningeal lymphatic drainage deficit due to peripheral chronic infection/inflammation may be responsible for increased EAF and cortical dysplasia in ASD individuals and, possibly, for some of the symptoms typical of the disorder.
527 citations
••
Novo Nordisk1, German Cancer Research Center2, University of Zurich3, University of Barcelona4, Newcastle University5, Medical University of Vienna6, University of Tübingen7, University Hospital Heidelberg8, Weizmann Institute of Science9, Max Planck Society10, Technische Universität München11, Heidelberg University12, Icahn School of Medicine at Mount Sinai13, National and Kapodistrian University of Athens14, University of Turin15, University of Cambridge16, University of Florence17, Paris Diderot University18, Humanitas University19, Hannover Medical School20, University of Hamburg21, University of Mainz22, University of Düsseldorf23, Memorial Sloan Kettering Cancer Center24, Cornell University25, Harvard University26, University of Cologne27, Leibniz Association28, University of Bern29, Mount Sinai Hospital30, University of Texas MD Anderson Cancer Center31, Kindai University32, Taipei Veterans General Hospital33, National Yang-Ming University34, French Institute of Health and Medical Research35, University of Grenoble36, Imperial College London37, Catalan Institution for Research and Advanced Studies38
TL;DR: The progressive accumulation of exhausted, unconventionally activated CD8+PD1+ T cells in NASH-affected livers provides a rationale for stratification of patients with HCC according to underlying aetiology in studies of immunotherapy as a primary or adjuvant treatment.
Abstract: Hepatocellular carcinoma (HCC) can have viral or non-viral causes1-5. Non-alcoholic steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved for treating HCC, but biomarker-based stratification of patients for optimal response to therapy is an unmet need6,7. Here we report the progressive accumulation of exhausted, unconventionally activated CD8+PD1+ T cells in NASH-affected livers. In preclinical models of NASH-induced HCC, therapeutic immunotherapy targeted at programmed death-1 (PD1) expanded activated CD8+PD1+ T cells within tumours but did not lead to tumour regression, which indicates that tumour immune surveillance was impaired. When given prophylactically, anti-PD1 treatment led to an increase in the incidence of NASH-HCC and in the number and size of tumour nodules, which correlated with increased hepatic CD8+PD1+CXCR6+, TOX+, and TNF+ T cells. The increase in HCC triggered by anti-PD1 treatment was prevented by depletion of CD8+ T cells or TNF neutralization, suggesting that CD8+ T cells help to induce NASH-HCC, rather than invigorating or executing immune surveillance. We found similar phenotypic and functional profiles in hepatic CD8+PD1+ T cells from humans with NAFLD or NASH. A meta-analysis of three randomized phase III clinical trials that tested inhibitors of PDL1 (programmed death-ligand 1) or PD1 in more than 1,600 patients with advanced HCC revealed that immune therapy did not improve survival in patients with non-viral HCC. In two additional cohorts, patients with NASH-driven HCC who received anti-PD1 or anti-PDL1 treatment showed reduced overall survival compared to patients with other aetiologies. Collectively, these data show that non-viral HCC, and particularly NASH-HCC, might be less responsive to immunotherapy, probably owing to NASH-related aberrant T cell activation causing tissue damage that leads to impaired immune surveillance. Our data provide a rationale for stratification of patients with HCC according to underlying aetiology in studies of immunotherapy as a primary or adjuvant treatment.
526 citations
••
A. Abada1, Marcello Abbrescia2, Marcello Abbrescia3, Shehu S. AbdusSalam4 +1491 more•Institutions (239)
TL;DR: In this article, the authors present the second volume of the Future Circular Collider Conceptual Design Report, devoted to the electron-positron collider FCC-ee, and present the accelerator design, performance reach, a staged operation scenario, the underlying technologies, civil engineering, technical infrastructure, and an implementation plan.
Abstract: In response to the 2013 Update of the European Strategy for Particle Physics, the Future Circular Collider (FCC) study was launched, as an international collaboration hosted by CERN. This study covers a highest-luminosity high-energy lepton collider (FCC-ee) and an energy-frontier hadron collider (FCC-hh), which could, successively, be installed in the same 100 km tunnel. The scientific capabilities of the integrated FCC programme would serve the worldwide community throughout the 21st century. The FCC study also investigates an LHC energy upgrade, using FCC-hh technology. This document constitutes the second volume of the FCC Conceptual Design Report, devoted to the electron-positron collider FCC-ee. After summarizing the physics discovery opportunities, it presents the accelerator design, performance reach, a staged operation scenario, the underlying technologies, civil engineering, technical infrastructure, and an implementation plan. FCC-ee can be built with today’s technology. Most of the FCC-ee infrastructure could be reused for FCC-hh. Combining concepts from past and present lepton colliders and adding a few novel elements, the FCC-ee design promises outstandingly high luminosity. This will make the FCC-ee a unique precision instrument to study the heaviest known particles (Z, W and H bosons and the top quark), offering great direct and indirect sensitivity to new physics.
526 citations
••
TL;DR: RPR, defined in the presence of P2Y12 reaction unit values above this cutoff, was found to be a significant and independent predictor of cardiovascular death and nonfatal MI in a model that adjusted for cardiovascular risk factors, renal failure, reduced left ventricular ejection fraction, multivessel disease, total stent length, bifurcation lesions, number of lesions treated, and type of stent.
Abstract: Background— The clinical impact of platelet aggregation assessed by point-of-care assays is unknown. We sought to evaluate whether high residual platelet reactivity (RPR) to ADP during clopidogrel therapy, measured by a point-of-care assay, predicts adverse clinical events in acute coronary syndrome patients undergoing percutaneous coronary intervention. Methods and Results— We used the VerifyNow P2Y12 assay (Accumetrics Inc, San Diego, Calif) to determine RPR to ADP in 683 patients with acute coronary syndrome undergoing dual-antiplatelet therapy who underwent percutaneous coronary intervention with bare-metal or drug-eluting stent implantation. All patients received a single 600-mg clopidogrel loading dose followed by 75 mg of clopidogrel daily and 100 to 325 mg of aspirin daily. The end points of the study at follow-up of 12 months were cardiovascular death, nonfatal myocardial infarction (MI), and target-vessel revascularization. At a 12-month follow-up, we found 51 ischemic events (24 cardiovascular ...
525 citations
Authors
Showing all 27699 results
Name | H-index | Papers | Citations |
---|---|---|---|
Charles A. Dinarello | 190 | 1058 | 139668 |
D. M. Strom | 176 | 3167 | 194314 |
Gregory Y.H. Lip | 169 | 3159 | 171742 |
Christopher M. Dobson | 150 | 1008 | 105475 |
Dirk Inzé | 149 | 647 | 74468 |
Thomas Hebbeker | 148 | 1984 | 114004 |
Marco Zanetti | 145 | 1439 | 104610 |
Richard B. Devereux | 144 | 962 | 116403 |
Gunther Roland | 141 | 1471 | 100681 |
Markus Klute | 139 | 1447 | 104196 |
Tariq Aziz | 138 | 1646 | 96586 |
Guido Tonelli | 138 | 1458 | 97248 |
Giorgio Trinchieri | 138 | 433 | 78028 |
Christof Roland | 137 | 1308 | 96632 |
Christoph Paus | 137 | 1585 | 100801 |